|
|
Dear Elysium Community,
Today I’m sharing our most significant announcement since Elysium launched in 2015:
The Elysium Longevity Institute (or TELI,
as it’s known by our team).
TELI is a physician-led platform for personalized longevity medicine—a single, comprehensive program built on diagnostics and the latest science, designed to provide protocols that maximize healthspan.
Years in development,
The Institute will offer personalized prescriptions, injectables, peptides, and more in a first-of-its-kind program—guided by leading scientists and clinicians.
For over a decade, Elysium has led the way in commercializing longevity research—from NAD+ to brain aging to biological age, and more. That work has made Elysium the world’s most clinically successful longevity company, while others have played catch up. Now, we see a new opportunity: As demand for serious longevity care accelerates, the category needs a higher standard. TELI is built to set it.
Ahead of our summer launch, we are opening the waitlist to the Elysium community
first. Claim your place and refer family and friends before we open it up to the public. When TELI launches, the first enrollment wave will be capped at 10,000 members, and
we expect it to fill quickly.
Join the waitlist now. Additional enrollment will follow as fast as responsibly possible.
I’m deeply optimistic about what’s ahead—and I hope you will join us as we change how longevity medicine is practiced.
|
|
|
|
In good health,
|
|
Eric Marcotulli
Elysium Health co-founder and CEO
|
|
|
|
|
|
|
|
|